Clinical Trial

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Protocol Amendment History 2 changes
notable Trial sites expanded: 10 -> 14 locations 2026-05-16
notable Trial sites expanded: 6 -> 10 locations 2026-04-25
Trial Details
NCT Number NCT07223138
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Arthritis, Psoriatic
Enrollment 1,560 participants
Start Date 2025-11-13
Primary Completion 2028-02-04 (estimated)
Study Completion 2028-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-11